Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1974 Nov;6(5):598–602. doi: 10.1128/aac.6.5.598

Assessment of Cytosine Arabinoside as an Antiviral Agent in Humans

Carl B Lauter a,1, Elizabeth J Bailey a, A Martin Lerner a
PMCID: PMC444699  PMID: 15825312

Abstract

Cytotoxicity, minimal inhibitory concentrations of herpesviruses, and pharmacokinetic studies of cytosine arabinoside (ara-C) were done. Ara-C compared favorably with idoxuridine in in vitro studies of antiviral activity versus herpes simplex, varicella-zoster, and cytomegalovirus. However, ara-C was 10 times more toxic to tissue cultures, and concentrations in serum and urine of three patients who were given ara-C at acceptable dosages (1 mg/kg per day) were not measurable by our assay. These studies predict that ara-C is not likely to be a useful antiviral agent in humans because its therapeutic to toxic ratio approaches unity. These predictions of little clinical efficacy seem now to have been confirmed by clinical trails in humans. Pharmacokinetic studies outlined here should precede and help formulate controlled clinical trials of potential antiviral agents in humans.

Full text

PDF
598

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BUTHALA D. A. CELL CULTURE STUDIES ON ANTIVIRAL AGENTS. I. ACTION OF CYTOSINE ARABINOSIDE AND SOME COMPARISONS WITH 5-IODO-2-DEOXYURIDINE. Proc Soc Exp Biol Med. 1964 Jan;115:69–77. doi: 10.3181/00379727-115-28834. [DOI] [PubMed] [Google Scholar]
  2. Ben-Porat T., Brown M., Kaplan A. S. Effect of 1-beta-D-arabinofuranosylcytosine on DNA synthesis. II. In rabbit kidney cells infected with herpes viruses. Mol Pharmacol. 1968 Mar;4(2):139–146. [PubMed] [Google Scholar]
  3. Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
  4. Creasey W. A., Papac R. J., Markiw M. E., Calabresi P., Welch A. D. Biochemical and pharmacological studies with 1-beta-D-arabinofuranosylcytosine in man. Biochem Pharmacol. 1966 Oct;15(10):1417–1428. doi: 10.1016/0006-2952(66)90186-9. [DOI] [PubMed] [Google Scholar]
  5. Davis C. M., VanDersarl J. V., Coltman C. A., Jr Failure of cytarabine in varicella-zoster infections. JAMA. 1973 Apr 2;224(1):122–123. [PubMed] [Google Scholar]
  6. Dixon R. L., Adamson R. H. Antitumor activity and pharmacologic disposition of cytosine arabinoside (NSC-63878). Cancer Chemother Rep. 1965 Oct;48:11–16. [PubMed] [Google Scholar]
  7. Feldman S., Hughes W. T., Kim H. Y. Herpes zoster in children with cancer. Am J Dis Child. 1973 Aug;126(2):178–184. doi: 10.1001/archpedi.1973.02110190156009. [DOI] [PubMed] [Google Scholar]
  8. Fiala M., Chow A., Guze L. B. Susceptibility of herpesviruses to cytosine arabinoside: standardization of susceptibility test procedure and relative resistance of herpes simplex type 2 strains. Antimicrob Agents Chemother. 1972 Apr;1(4):354–357. doi: 10.1128/aac.1.4.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gray G. D., Nichol F. R., Mickelson M. M., Camiener G. W., Gish D. T., Kelly R. C., Wechter W. J., Moxley T. E., Neil G. L. Immunosuppressive, antiviral and antitumor activities of cytarabine derivatives. Biochem Pharmacol. 1972 Feb 15;21(4):465–475. doi: 10.1016/0006-2952(72)90319-x. [DOI] [PubMed] [Google Scholar]
  10. Gray G. D. The immunosuppressive activity of ara-C (cytarabine) and derivatives. Transplant Proc. 1973 Sep;5(3):1203–1209. [PubMed] [Google Scholar]
  11. Hall T. C., Wilfert C., Jaffe N., Traggis D., Lux S., Rompf P., Katz S. Treatment of varicella-zoster with cytosine arabinoside. Trans Assoc Am Physicians. 1969;82:201–210. [PubMed] [Google Scholar]
  12. Haus E., Halberg F., Pauly J. E., Cardoso S., Kühl J. F., Sothern R. B., Shiotsuka R. N., Hwang D. S. Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system. Science. 1972 Jul 7;177(4043):80–82. doi: 10.1126/science.177.4043.80. [DOI] [PubMed] [Google Scholar]
  13. Ho D. H., Frei E., 3rd Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther. 1971 Nov-Dec;12(6):944–954. doi: 10.1002/cpt1971126944. [DOI] [PubMed] [Google Scholar]
  14. Hryniuk W., Foerster J., Shojania M., Chow A. Cytarabine for herpesvirus infections. JAMA. 1972 Feb;219(6):715–718. [PubMed] [Google Scholar]
  15. Juel-Jensen B. E. Herpes simplex and zoster. Br Med J. 1973 Feb 17;1(5850):406–410. doi: 10.1136/bmj.1.5850.406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. KAUFMAN H. E., CAPELLA J. A., MALONEY E. D., ROBBINS J. E., COOPER G. M., UOTILA M. H. CORNEAL TOXICITY OF CYTOSINE ARABINOSIDE. Arch Ophthalmol. 1964 Oct;72:535–540. doi: 10.1001/archopht.1964.00970020535019. [DOI] [PubMed] [Google Scholar]
  17. Lerner A. M., Bailey E. J. Concentrations of idoxuridine in serum, urine, and cerebrospinal fluid of patients with suspected diagnoses of Herpesvirus hominis encephalitis. J Clin Invest. 1972 Jan;51(1):45–49. doi: 10.1172/JCI106795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lerner A. M., Bailey E. J., Nolan D. C. Complement-requiring neutralizing antibodies in Herpesvirus hominis encephalitis. J Immunol. 1970 Mar;104(3):607–615. [PubMed] [Google Scholar]
  19. Mitchell M. S., Wade M. E., DeConti R. C., Bertino J. R., Calabresi P. Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Ann Intern Med. 1969 Mar;70(3):535–547. doi: 10.7326/0003-4819-70-3-535. [DOI] [PubMed] [Google Scholar]
  20. Nolan D. C., Lauter C. B., Lerner A. M. Idoxuridine in herpes simplex virus (type 1) encephalitis. Experience with 29 cases in Michigan, 1966 to 1971. Ann Intern Med. 1973 Feb;78(2):243–246. doi: 10.7326/0003-4819-78-2-243. [DOI] [PubMed] [Google Scholar]
  21. Panitch H. S., Baringer J. R. Experimental herpes simplex encephalitis. Treatment with pyrimidine nucleosides. Arch Neurol. 1973 Jun;28(6):371–375. doi: 10.1001/archneur.1973.00490240031003. [DOI] [PubMed] [Google Scholar]
  22. RAPP F. INHIBITION BY METABOLIC ANALOGUES OF PLAQUE FORMATION BY HERPES ZOSTER AND HERPES SIMPLEX VIRUSES. J Immunol. 1964 Oct;93:643–648. [PubMed] [Google Scholar]
  23. Renis H. E. Comparison of cytotoxicity and antiviral activity of 1-beta-D-arabino-furanosyl-5-iodocytosine with related compounds. Cancer Res. 1970 Jan;30(1):189–194. [PubMed] [Google Scholar]
  24. Stevens D. A., Jordan G. W., Waddell T. F., Merigan T. C. Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N Engl J Med. 1973 Oct 25;289(17):873–878. doi: 10.1056/NEJM197310252891701. [DOI] [PubMed] [Google Scholar]
  25. Stevens D. A., Merigan T. C. Uncertain role of cytosine arabinoside in varicella infection of compromised hosts. J Pediatr. 1972 Sep;81(3):562–565. doi: 10.1016/s0022-3476(72)80192-6. [DOI] [PubMed] [Google Scholar]
  26. TALLEY R. W., VAITKEVICIUS V. K. Megaloblastosis produced by a cytosine antagonist, 1-beta-D-arabinofuranosylcytosine. Blood. 1963 Mar;21:352–362. [PubMed] [Google Scholar]
  27. Talley R. W., O'Bryan R. M., Tucker W. G., Loo R. V. Clinical pharmacology and human antitumor activity of cytosine arabinoside. Cancer. 1967 May;20(5):809–816. doi: 10.1002/1097-0142(1967)20:5<809::aid-cncr2820200536>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  28. Walker W. E., Waisbren B. A., Martins R. R., Batayias G. E. A method for determining sensitivities of antiviral drugs in vitro for possible use as clinical consultation. Am J Clin Pathol. 1971 Dec;56(6):687–692. doi: 10.1093/ajcp/56.6.687. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES